BioArctic AB Class B

As of June 30, 2026, BioArctic AB Class B carries a market capitalization of 2.65B, placing it among publicly traded companies globally. Its enterprise value stands at 2.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioArctic AB Class B's next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, BioArctic AB Class B has 88.72M shares outstanding.

As of June 30, 2026, BioArctic AB Class B trades at a trailing price-to-earnings ratio of 278.22. The price-to-sales ratio is 29.29, and the price-to-book ratio stands at 14.57.

As of June 30, 2026, BioArctic AB Class B trades at an EV/EBITDA multiple of 131.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 27.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 131.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BioArctic AB Class B trades at an EV/FCF ratio of 110.89, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.48B versus a market cap of 2.65B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioArctic AB Class B maintains a current ratio of 3.99, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.49, indicating elevated leverage, while an interest coverage ratio of 22.93 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioArctic AB Class B posted a return on equity (ROE) of 5.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.23 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.22, useful for judging operating efficiency across full business cycles. The company generates approximately 724,059.42 in revenue per employee across its workforce of 125.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BioArctic AB Class B recorded 12.92M in income tax expense. That works out to an effective tax rate of 57.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.45M, leaving 9.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BioArctic AB Class B's stock has gained approximately 1.27% over the past 52 weeks. The 50-day moving average sits at 28.28, while the 200-day moving average is 29.08.

Over the twelve months ended June 30, 2026, BioArctic AB Class B generated 90.51M in revenue and converted that into 9.53M in net income, yielding earnings per share of 0.11. EBITDA reached 18.85M, while operating income came in at 18.85M.

As of June 30, 2026, BioArctic AB Class B holds 179.66M in cash and equivalents against 8.18M in total debt, resulting in a net debt position of -97.63M. Total book value stands at 182.03M, with working capital of 181.14M providing operational flexibility.

BioArctic AB Class B produced 22.03M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BioArctic AB Class B posted a gross margin of 93.17, reflecting its pricing power and cost economics. The operating margin of 20.83 and net profit margin of 10.53 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.83, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioArctic AB Class B shareholders.